Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer
An erratum to this article was published (J Clin Endocrinol Metab, 16 Sep 2025 ↗)
Authors' conclusion
The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes, and the new drug apatinib demonstrates promise for potentially superior performance.
Study context
- Population
- Patients with radioiodine-refractory DTC (radioiodine-refractory differentiated thyroid cancer (RR-DTC))
- Participants
- 3,270 patients8 randomized controlled trials (RCTs)17 single-arm studies
- Comparison
- Targeted drug therapy vs control in RR-DTC
- Outcome
- Progression-free survival (PFS) and overall survival (OS)
Pooled result
As reported in the abstract
Estimate (95% CI)P value
Targeted therapy
HR (PFS) 0.35(0.23–0.53)
P < 0.00001Targeted therapy
HR (OS) 0.53(0.32–0.86)
P < 0.00001Further pooled results
Objective response rate (ORR) and disease control rate (DCR)
| Estimate | P value | ||
|---|---|---|---|
| Targeted therapy | RR (ORR) 27.63 (95% CI 12.39–61.61) | P < 0.00001 | |
| Targeted therapy | RR (DCR) 1.66 (95% CI 1.48–1.86) | P < 0.00001 | |
| 0.050.21520Ratio (log scale) |
Apatinib subgroup: ORR and DCR (effect size)
- Apatinib ORR effect size (ES)
- 0.66 (95% CI 0.49-0.83, P < .00001)
- Apatinib DCR ES
- 0.95 (95% CI 0.91-1.00, P < .00001)
- Apatinib had the best effect on ORR and DCR
Safety
- Common adverse events: hypertension, diarrhea, proteinuria, fatigue
Original publication
Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →